HARD DECISIONS IN INTENSIVE CARE UNIT

Intensivecareunitkapak

HEPATORENAL SYNDROME

Fatma Erseven

Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Department of Intevsive Care, Ankara, Türkiye

Erseven F. Hepatorenal Syndrome. In: Turan S, editor. Hard Decisions in Intensive Care Unit. 1st ed. Ankara: Türkiye Klinikleri; 2025. p.117-131.

ABSTRACT

Hepatorenal Syndrome (HRS) is the rapid deterioration of kidney functions in severely cirrhotic patients. The pathophysiology comprises circulatory dysfunction, systemic inflammation and bacterial transformation, renal (tubular) dysfunction, hepatorenal reflex, adrenal insufficiency, and abdominal hypertension. Currently, two forms of HRS are recognised according to acute or non-acute kidney injury (AKI): HRS-AKI and HRS-NAKI (non-AKI). This section discusses the new definition and diagnosis of HRS according to the new criteria, differential diagnosis, mechanisms for the development of HRS, principles of established treatment and management of HRS, and novel therapeutic approaches of HRS.

Keywords: Hepatorenal syndrome; Intensive care unit; Acute renal injury; Cirrhotic patient; Liver; Cirrhosis

Referanslar

  1. Galbois A, Trompette ML, Das V, Boëlle PY, Carbonell N, Thabut D, et al. Improvement in the prognosis of cirrhotic patients admitted to an intensive care unit, a retrospective study. Eur J Gastroenterol Hepatol. 2012;24(8):897-904. [Crossref]  [PubMed]
  2. Baudry T, Hernu R, Valleix B, Jahandiez V, Faucher E, Simon M, et al. Cirrhotic patients admitted to the ICU with septic shock: Factors predicting short and long-term outcome. Shock. 2019;52(4):408-13. [Crossref]  [PubMed]
  3. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. J Hepatol. 2006;44(1):217-31. [Crossref]  [PubMed]
  4. Gustot T, Stadlbauer V, Laleman W, Alessandria C, Thursz M. Transition to decompensation and acute-onchronic liver failure: Role of predisposing factors and precipitating events. J Hepatol. 2021;75:S36-48. [Crossref]  [PubMed]
  5. Fleming KM, Aithal GP, Card TR, West J. All-cause mortality in people with cirrhosis compared with the general population: A population-based cohort study. Liver International. 2012;32(1):79-84. [Crossref]  [PubMed]
  6. Hepatorenal Syndrome [Internet]. [cited 2025 Jan 10]. Available from: [Link]
  7. Wadei HM, Gonwa TA. Hepatorenal syndrome in the intensive care unit. J Intensive Care Med. 2013;28(2):79-92. [Crossref]  [PubMed]
  8. Nadim MK, Kellum JA, Davenport A, Wong F, Davis C, Pannu N, et al. Hepatorenal syndrome: The 8th international consensus conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care [Internet]. 2012;16(1):R23. Available from: [Crossref]  [PubMed]  [PMC]
  9. Gonwa TA. Hepatorenal Syndrome [Internet]. 2022 [cited 2025 Jan 12]. Available from: [Link]
  10. Acevedo JG, Cramp ME. Hepatorenal syndrome: Update on diagnosis and therapy. World J Hepatol. 2017;9(6):293-9. [Crossref]  [PubMed]  [PMC]
  11. Qadir A, Khan A, Ali B, Umar M, Talha M, Ahmad A, et al. Incidence predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Journal of Population and Therapeutics and Clinical Pharmacology. 2023;30(17):1133-9. [Crossref]
  12. Roy P, Minhaz N, Shah-Riar P, Simona SY, Tasha T, Binte Hasan T, et al. A comprehensive systematic review of the latest management strategies for hepatorenal syndrome: a complicated syndrome to tackle. Cureus. 2023;15(8). [Crossref]  [PubMed]
  13. Ranasinghe IR, Sharma B, Bashir K. Hepatorenal Syndrome. 2023 Aug 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. [Link]
  14. Nadim MK, Garcia-Tsao G. Acute kidney injury in patients with cirrhosis. New England Journal of Medicine. 2023;388(8):733-45. [Crossref]  [PubMed]
  15. Biggins SW, Angeli P, Garcia-Tsao G, Ginès P, Ling SC, Nadim MK, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(2):1014-48. [Crossref]  [PubMed]
  16. Nadim MK, Forni LG, Ostermann M; ADQI 29/ICA Expert Panel. Hepatorenal syndrome in the intensive care unit. Intensive Care Med. 2024;50(6):978-981. [Crossref]  [PubMed]
  17. Angeli P, Garcia-Tsao G, Nadim MK, Parikh CR. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. J Hepatol. 2019 Oct;71(4):811-822. [Crossref]  [PubMed]  [PMC]
  18. Tapper EB, Parikh ND. Diagnosis and management of cirrhosis and its complications: a review. JAMA. 2023;329(18):1589-602. [Crossref]  [PubMed]  [PMC]
  19. Velez JCQ, Therapondos G, Juncos LA. Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis. Nat Rev Nephrol. 2020;16(3):137-155. [Crossref]  [PubMed]
  20. Nadim MK, Kellum JA, Forni L, Francoz C, Asrani SK, Ostermann M, et al. Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting. J Hepatol. 2024;81(1):163-83. [Crossref]  [PubMed]  [PMC]
  21. Angeli P, Ginès P, Wong F, Bernardi M, Boyer TD, Gerbes A, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites. J Hepatol. 2015;62(4):968-74. [Crossref]  [PubMed]
  22. Ruiz-Del-Arbol L, Monescillo A, Arocena C, Valer P, Ginès P, Moreira V, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology. 2005;42(2):439-47. [Crossref]  [PubMed]
  23. Solé C, Solà E, Huelin P, Carol M, Moreira R, Cereijo U, et al. Characterization of inflammatory response in hepatorenal syndrome: Relationship with kidney outcome and survival. Liver International. 2019;39(7):1246-55. [Crossref]  [PubMed]  [PMC]
  24. Chang Y, Qi X, Li Z, Wang F, Wang S, Zhang Z, et al. Hepatorenal syndrome: Insights into the mechanisms of intra-abdominal hypertension. Int J Clin Exp Pathol. 2013;6(11):2523-8. [PubMed]
  25. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988;8(5):1151-7. [Crossref]  [PubMed]
  26. Kaur H, Premkumar M. Diagnosis and management of cirrhotic cardiomyopathy. J Clin Exp Hepatol. 2022;12(1):186-99. [Crossref]  [PubMed]  [PMC]
  27. Silva ACS, Miranda AS, Rocha NP, Teixeira AL. Renin angiotensin system in liver diseases: Friend or foe? World J Gastroenterol. 2017;23(19):3396-406. [Crossref]  [PubMed]  [PMC]
  28. Bucsics T, Krones E. Renal dysfunction in cirrhosis: Acute kidney injury & the hepatorenal syndrome. Gastroenterol Rep (Oxf). 2017;5(2):127-37. [Crossref]  [PubMed]  [PMC]
  29. Bera C, Wong F. Management of hepatorenal syndrome in liver cirrhosis: a recent update. Therap Adv Gastroenterol. 2022;15:1-19. [Crossref]  [PubMed]  [PMC]
  30. Jarajapu Y. Cardiovascular protective arm of renin-angiotensin system. In: Dhalla NS, Bhullar SK, Shah AK, eds. The Renin Angiotensin System in Cardiovascular Disease. Advances in Biochemistry in Health and Disease, vol 24. 2023. p.363-375 [Crossref]
  31. Varga Z V, Erdelyi K, Paloczi J, Cinar R, Zsengeller ZK, Jourdan T, et al. Disruption of renal arginine metabolism promotes kidney injury in hepatorenal syndrome in mice. Hepatology. 2018;68(4):1519-33. [Crossref]  [PubMed]  [PMC]
  32. Wilson DN. Prostaglandins and kidney function : A comparison between the cortical and inner medullary collecting duct on prostaglandin production 2019; Theses & Dissertations. 370. [Link]
  33. Sampaio MS, Martin P, Bunnapradist S. Renal dysfunction in end-stage liver disease and post-liver transplant. Clin Liver Dis. 2014;18(3):543-60. [Crossref]  [PubMed]
  34. Thabut D, Massard J, Gangloff A, Carbonell N, Francoz C, Nguyen-Khac E, et al. Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure. Hepatology. 2007;46(6):1872-82. [Crossref]  [PubMed]
  35. Moreau R. The Pathogenesis of ACLF: The inflammatory response and immune function. Semin Liver Dis. 2016;36(2):133-40. [Crossref]  [PubMed]
  36. Cheng XS, Tan JC, Kim WR. Management of renal failure in end-stage liver disease: A critical appraisal. Liver Transplantation. 2016;22(12):1710-9. [Crossref]  [PubMed]
  37. Barreto R, Fagundes C, Guevara M, Solà E, Pereira G, Rodríguez E, et al. Type-1 hepatorenal syndrome associated with infections in cirrhosis: Natural history, outcome of kidney function, and survival. Hepatology. 2014;59(4):1505-13. [Crossref]  [PubMed]
  38. Arroyo V, Angeli P, Moreau R, Jalan R, Clària J, Trebicka J, et al. The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis. J Hepatol. 2021;74(3):670-85. [Crossref]  [PubMed]
  39. Such J, Hillebrand DJ, Guarner C, Berk L, Zapater P, Westengard J, et al. Nitric oxide in ascitic fluid is an independent predictor of the development of renal impairment in patients with cirrhosis and spontaneous bacterial peritonitis. Eur J Gastroenterol Hepatol. 2004;16(6):571-7. [Crossref]  [PubMed]
  40. Shah N, Mohamed FE, Jover-Cobos M, Macnaughtan J, Davies N, Moreau R, et al. Increased renal expression and urinary excretion of TLR4 in acute kidney injury associated with cirrhosis. Liver International. 2013;33(3):398-409. [Crossref]  [PubMed]
  41. Kacsó IM, Borza GM, Ciuce CC, Bîrsan A, Apostu RC, Dindelegan GC, et al. Expression of TLR4 protein is reduced in chronic renal failure: Evidence from an experimental model of nephron reduction. Romanian Journal of Morphology and Embryology. 2015;56(1):93-9. [PubMed]
  42. Mindikoglu AL, Dowling TC, Wong-You-Cheong JJ, Christenson RH, Magder LS, Hutson WR, et al. A pilot study to evaluate renal hemodynamics in cirrhosis by simultaneous glomerular filtration rate, renal plasma flow, renal resistive indices and biomarkers measurements. Am J Nephrol. 2014;39(6):543-52. [Crossref]  [PubMed]  [PMC]
  43. Mandorfer M, Hecking M. The renaissance of cholemic nephropathy: A likely underestimated cause of renal dysfunction in liver disease. Hepatology. 2019;69(5):1858-60. [Crossref]  [PubMed]
  44. Kanduri SR, Velez JCQ. Kidney dysfunction in the setting of liver failure: Core Curriculum 2024. American Journal of Kidney Diseases. 2024;83(3):386-401. [Crossref]  [PubMed]
  45. Wentworth BJ, Siragy HM. Adrenal insufficiency in cirrhosis. J Endocr Soc. 2022;6(10):1-11. [Crossref]  [PubMed]  [PMC]
  46. Piano S, Favaretto E, Tonon M, Antonelli G, Brocca A, Sticca A, et al. Including relative adrenal insufficiency in definition and classification of acute-on-chronic liver failure. Clinical Gastroenterology and Hepatology. 2020;18(5):1188-1196. e3. [Crossref]  [PubMed]
  47. Acevedo J, Fernández J, Prado V, Silva A, Castro M, Pavesi M, et al. Relative adrenal insufficiency in decompensated cirrhosis: Relationship to short-term risk of severe sepsis, hepatorenal syndrome, and death. Hepatology. 2013;58(5):1757-65. [Crossref]  [PubMed]
  48. Fede G, Spadaro L, Tomaselli T, Privitera G, Germani G, Tsochatzis E, et al. Adrenocortical dysfunction in liver disease: A systematic review. Hepatology. 2012;55(4):1282-91. [Crossref]  [PubMed]
  49. Singh RR, Walia R, Sachdeva N, Bhalla A, Singh A, Singh V. Relative adrenal insufficiency in cirrhotic patients with ascites (hepatoadrenal syndrome). Digestive and Liver Disease. 2018;50(11):1232-7. [Crossref]  [PubMed]
  50. Samoni S, Husain-Syed F, De Rosa S, Ronco C. Cardio-pulmonary-renal interactions. G Ital Nefrol. 2017;34(22):162-77. [PubMed]
  51. Verbrugge FH, Dupont M, Steels P, Grieten L, Malbrain M, Tang WHW, et al. Abdominal contributions to cardiorenal dysfunction in congestive heart failure. J Am Coll Cardiol. 2013;62(6):485-95. [Crossref]  [PubMed]
  52. Malbrain MLNG, Cheatham ML, Kirkpatrick A, Sugrue M, Parr M, De Waele J, et al. Results from the International Conference of Experts on intra-abdominal hypertension and abdominal compartment syndrome. I. Definitions. Intensive Care Med. 2006;32(11):1722-32. [Crossref]  [PubMed]
  53. Chang HJ, Yang J, Kim SC, Kim MG, Jo SK, Cho WY, et al. Intra-abdominal hypertension does not predict renal recovery or in-hospital mortality in critically ill patients with acute kidney injury. Kidney Res Clin Pract. 2015;34(2):103-8. [Crossref]  [PubMed]  [PMC]
  54. Lee JE. Increased intra-abdominal pressure in acute kidney injury: A cause or an effect? Kidney Res Clin Pract. 2015;34(2):67-8. [Crossref]  [PubMed]  [PMC]
  55. Nassar M, Nso N, Medina L, Ghernautan V, Novikov A, El-Ijla A, et al. Liver kidney crosstalk: Hepatorenal syndrome. World J Hepatol. 2021;13(9):1058-68. [Crossref]  [PubMed]  [PMC]
  56. Ming Z, Smyth DD, Lautt WW. Decreases in portal flow trigger a hepatorenal reflex to inhibit renal sodium and water excretion in rats: Role of adenosine. Hepatology. 2002;35(1):167-75. [Crossref]  [PubMed]
  57. Ming Z, Lautt WW. Intrahepatic adenosine-mediated activation of hepatorenal reflex is via A1 receptors in rats. Can J Physiol Pharmacol. 2006;84(11):1177-84. [Crossref]  [PubMed]
  58. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):179-84. [Crossref]  [PubMed]
  59. Simonetto DA, Gines P, Kamath PS. Hepatorenal syndrome: pathophysiology, diagnosis, and management. BMJ. 2020;370:m2687. [Crossref]  [PubMed]
  60. Huelin P, Piano S, Solà E, Stanco M, Solé C, Moreira R, et al. Validation of a staging system for acute kidney injury in patients with cirrhosis and association with acuteon-chronic liver failure. Clinical Gastroenterology and Hepatology. 2017;15(3):438-445.e5. [Crossref]  [PubMed]
  61. Maciel AT, Vitorio D, Osawa EA. Urine biochemistry assessment in the sequential evaluation of renal function: Time to think outside the box. Front Med (Lausanne). 2022;9. [Crossref]  [PubMed]  [PMC]
  62. Gowda YHS, Jagtap N, Karyampudi A, Rao NP, Deepika G, Sharma M, et al. Fractional excretion of sodium and urea in differentiating acute kidney injury phenotypes in decompensated cirrhosis. J Clin Exp Hepatol. 2022;12(3):899-907. [Crossref]  [PubMed]  [PMC]
  63. Arora MS, Kaushik R, Ahmad S, Kaushik RM. Profile of acute kidney injury in patients with decompensated cirrhosis at a tertiary-care center in Uttarakhand, India. Digestive Diseases. 2020;38(4):335-43. [Crossref]  [PubMed]
  64. Rahman M, Shad F, Smith MC. Acute kidney injury: A guide to diagnosis and management. Am Fam Physician. 2012;86(7):631-9. [PubMed]
  65. Khan S, Linganna M. Diagnosis and management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome. Cleve Clin J Med. 2023;90(4):209-13. [Crossref]  [PubMed]
  66. Wong F, O'Leary JG, Reddy KR, Garcia-Tsao G, Fallon MB, Biggins SW, et al. Acute kidney injury in cirrhosis: baseline serum creatinine predicts patient outcomes. American Journal of Gastroenterology. 2017;112(7):1103- 10. [Crossref]  [PubMed]
  67. Angeli P, Bernardi M, Villanueva C, Francoz C, Mookerjee RP, Trebicka J, et al. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-60. [Crossref]  [PubMed]
  68. Velez JCQ, Nietert PJ. Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: A pooled analysis of clinical trials. American Journal of Kidney Diseases. 2011;58(6):928-38. [Crossref]  [PubMed]  [PMC]
  69. Garcia-Tsao G, Abraldes JG, Rich NE, Wong VWS. AGA Clinical practice update on the use of vasoactive drugs and intravenous albumin in cirrhosis: Expert review. Gastroenterology. 2024;166(1):202-10. [Crossref]  [PubMed]
  70. Hasan I, Rashid T, Chirila RM, Ghali P, Wadei HM. Hepatorenal syndrome: pathophysiology and evidence-based management update. Rom J Intern Med. 2021;59(3):227-61. [Crossref]  [PubMed]
  71. Cavallin M, Piano S, Romano A, Fasolato S, Frigo AC, Benetti G, et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study. Hepatology. 2016;63(3):983-92. [Crossref]  [PubMed]
  72. Alessandria C, Ottobrelli A, Debernardi-Venon W, Todros L, Cerenzia MT, Martini S, et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: A prospective, randomized, unblinded, pilot study. J Hepatol. 2007;47(4):499- 505. [Crossref]  [PubMed]
  73. Sharma P, Kumar A, Shrama BC, Sarin SK. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. American Journal of Gastroenterology. 2008;103(7):1689-97. [Crossref]  [PubMed]
  74. Singh V, Ghosh S, Singh B, Kumar P, Sharma N, Bhalla A, et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: A randomized study. J Hepatol. 2012;56(6):1293-8. [Crossref]  [PubMed]
  75. Belcher JM. Hepatorenal Syndrome: Pathophysiology, diagnosis, and treatment. Medical Clinics of North America. 2023;107(4):781-92. [Crossref]  [PubMed]
  76. Hiruy A, Nelson J, Zori A, Morelli G, Cabrera R, Kamel A. Standardized approach of albumin, midodrine and octreotide on hepatorenal syndrome treatment response rate. Eur J Gastroenterol Hepatol. 2021;33(1):102-6. [Crossref]  [PubMed]
  77. Bortoluzzi A, Ceolotto G, Gola E, Sticca A, Bova S, Morando F, et al. Positive cardiac inotropic effect of albumin infusion in rodents with cirrhosis and ascites: Molecular mechanisms. Hepatology. 2013;57(1):266-76. [Crossref]  [PubMed]
  78. Garcia-Martinez R, Andreola F, Mehta G, Poulton K, Oria M, Jover M, et al. Immunomodulatory and antioxidant function of albumin stabilises the endothelium and improves survival in a rodent model of chronic liver failure. J Hepatol. 2015;62(4):799-806. [Crossref]  [PubMed]
  79. Arora V, Maiwall R, Rajan V, Jindal A, Muralikrishna Shasthry S, Kumar G, et al. Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure. Hepatology. 2020;71(2):600-10. [Crossref]  [PubMed]
  80. Wong F, Pappas SC, Curry MP, Reddy KR, Rubin RA, Porayko MK, et al. Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. New England Journal of Medicine. 2021;384(9):818-28. [Crossref]  [PubMed]
  81. Sanyal AJ, Boyer TD, Frederick RT, Wong F, Rossaro L, Araya V, et al. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies. Aliment Pharmacol Ther. 2017;45(11):1390-402. [Crossref]  [PubMed]  [PMC]
  82. Ortega R, Ginès P, Uriz J, Cárdenas A, Calahorra B, De Las Heras D, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study. Hepatology. 2002;36(4):941-8. [Crossref]  [PubMed]
  83. Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: Results of a prospective, randomized, controlled clinical trial. Liver Transplantation. 2000;6(3):277-86. [Crossref]  [PubMed]
  84. Wallon G, Guth C, Guichon C, Thevenon S, Gazon M, Viale JP, et al. Extracorporeal albumin dialysis in liver failure with MARS and SPAD: A randomized crossover trial. Blood Purif. 2022;51(3):243-50. [Crossref]  [PubMed]
  85. Ripoll C, Platzer S, Franken P, Aschenbach R, Wienke A, Schuhmacher U, et al. Liver-HERO: hepatorenal syndrome-acute kidney injury (HRS-AKI) treatment with transjugular intrahepatic portosystemic shunt in patients with cirrhosis-a randomized controlled trial. Trials. 2023;24(1):1-14. [Crossref]  [PubMed]  [PMC]
  86. Bosch J. Salvage transjugular intrahepatic portosystemic shunt for uncontrolled variceal bleeding in patients with decompensated cirrhosis. J Hepatol. 2001;35(5):590-7. [Crossref]  [PubMed]
  87. Ginès P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, Del Arbol LR, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology. 2002;123(6):1839-47. [Crossref]  [PubMed]
  88. Lenhart A, Hussain S, Salgia R. Chances of renal recovery or liver transplantation after hospitalization for alcoholic liver disease requiring dialysis. Dig Dis Sci. 2018;63(10):2800-9. [Crossref]  [PubMed]
  89. McAllister S, Lai JC, Copeland TP, Johansen KL, McCulloch CE, Kwong YD, et al. Renal recovery and mortality risk among patients with hepatorenal syndrome receiving chronic maintenance dialysis. Kidney360. 2021;2(5):819-27. [Crossref]  [PubMed]  [PMC]
  90. Boyer TD, Sanyal AJ, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, Gülberg V, Sigal S, Bexon AS, Teuber P; Terlipressin Study Group. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1. Liver Transpl. 2011;17(11):1328-32. [Crossref]  [PubMed]  [PMC]
  91. Mahmud N. Selection for liver transplantation: Indications and evaluation. Curr Hepatol Rep. 2020;19(3):203-12. [Crossref]  [PubMed]  [PMC]
  92. Kamath PS, Kim WR. The model for end-stage liver disease (MELD). Hepatology. 2007;45(3):797-805. [Crossref]  [PubMed]
  93. Flamm SL, Wong F, Ahn J, Kamath PS. AGA Clinical practice update on the evaluation and management of acute kidney injury in patients with cirrhosis: Expert review. Clinical Gastroenterology and Hepatology. 2022;20(12):2707-16. [Crossref]  [PubMed]
  94. Nadim MK, Genyk YS, Tokin C, Fieber J, Ananthapanyasut W, Ye W, et al. Impact of the etiology of acute kidney injury on outcomes following liver transplantation: Acute tubular necrosis versus hepatorenal syndrome. Liver Transplantation. 2012;18(5):539-48. [Crossref]  [PubMed]
  95. Lizaola-Mayo B, Vargas HE. Hepatorenal syndrome-acute kidney injury in liver transplantation. Clinical Gastroenterology and Hepatology. 2023;21(10):S20-6. [Crossref]  [PubMed]
  96. Schmitz V, Laudi S, Moeckel F, Puhl G, Stockmann M, Tran ZV, et al. Chronic renal dysfunction following liver transplantation. Clin Transplant. 2008;22(3):333-40. [Crossref]  [PubMed]
  97. Bañares R, Nevens F, Larsen FS, Jalan R, Albillos A, Dollinger M, et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acuteon-chronic liver failure: The RELIEF trial. Hepatology. 2013;57(3):1153-62. [Crossref]  [PubMed]
  98. McKenzie TJ, Lillegard JB, Nyberg SL. Artificial and bioartificial liver support. Semin Liver Dis. 2008;28(2):210-7. [Crossref]  [PubMed]
  99. Tandon R, Froghi S. Artificial liver support systems. Journal of Gastroenterology and Hepatology (Australia). 2021;36(5):1164-79. [Crossref]  [PubMed]
  100. Fernández J, Lozano M, Torres M, Horrillo R, Afonso N, Núñez L, et al. Effect of plasma exchange with albumin replacement on albumin functionality and organ dysfunction in acute-on-chronic liver failure. JHEP Reports. 2024;6(4):101017. [Crossref]  [PubMed]  [PMC]
  101. Zhang Y, Dong R, Li Y, Yang X, Liu J, Ou S, et al. Efficacy and safety of plasma diafiltration: Review of case reports and case series. Therapeutic Apheresis and Dialysis. 2023;27(1):3-11. [Crossref]  [PubMed]
  102. Solà E, Lens S, Guevara M, Martín-llahí M, Fagundes C, Pereira G, et al. Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension. Hepatology. 2010;52(5):1783-90. [Crossref]  [PubMed]
  103. Snowdon VK, Lachlan NJ, Hoy AM, Hadoke PWF, Semple SI, Patel D, et al. Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial. PLoS Med. 2017;14(2):1-29. [Crossref]  [PubMed]  [PMC]
  104. Gifford FJ, Dunne PDJ, Weir G, Ireland H, Graham C, Tuck S, et al. A phase 2 randomised controlled trial of serelaxin to lower portal pressure in cirrhosis (STOPP). Trials. 2020;21(1):1-10. [Crossref]  [PubMed]  [PMC]
  105. Sassoli C, Nistri S, Chellini F, Bani D. Human recombinant relaxin (serelaxin) as anti-fibrotic agent: pharmacology, limitations and actual perspectives. Curr Mol Med. 2021;22(3):196-208. [Crossref]  [PubMed]
  106. Fedulenkova L V. Correction of portal hypertension and renal dysfunction with help of nebivolol and lizinopril in patients with hepatic cirrhosis. Eksp Klin Gastroenterol. 2009;(5):130-7. [PubMed]
  107. Atwa A, Hegazy R, Mohsen R, Yassin N, Kenawy S. Protective effects of the third generation vasodilatory Beta - Blocker nebivolol against D-galactosamine - Induced hepatorenal syndrome in rats. Open Access Maced J Med Sci. 2017;5(7):880-92. [Crossref]  [PubMed]  [PMC]
  108. Stine JG, Wang J, Cornella SL, Behm BW, Henry Z, Shah NL, et al. Treatment of type-1 hepatorenal syndrome with pentoxifylline: A randomized placebo controlled clinical trial. Ann Hepatol. 2018;17(2):300-6. [Crossref]  [PubMed]  [PMC]
  109. Caraceni P, Vargas V, Solà E, Alessandria C, de Wit K, Trebicka J, et al. The use of rifaximin in patients with cirrhosis. Hepatology. 2021;74(3):1660-73. [Crossref]  [PubMed]  [PMC]
  110. Zhao X, Yang T, Zhou J, Chen Y, Shen Q, Zhang J, et al. Fucoidan alleviates the hepatorenal syndrome through inhibition organic solute transporter α/β to reduce bile acids reabsorption. Current Research in Pharmacology and Drug Discovery. 2023;5:100159. [Crossref]  [PubMed]  [PMC]
  111. Fernández J, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology. 2007;133(3):818-24. [Crossref]  [PubMed]
  112. Assem M, Elsabaawy M, Abdelrashed M, Elemam S, Khodeer S, Hamed W, et al. Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study. Hepatol Int. 2016;10(2):377-85. [Crossref]  [PubMed]